Center Laboratories, Inc. (TPEX:4123)

Market Cap	30.09B -3.7%
Revenue (ttm)	1.57B -0.6%
Net Income	1.78B
EPS	2.28
Shares Out	746.53M
PE Ratio	17.70
Forward PE	n/a
Dividend	0.71 (1.77%)
Ex-Dividend Date	Oct 3, 2025

Volume	2,148,740
Average Volume	2,774,358
Open	40.40
Previous Close	40.30
Day's Range	39.50 - 40.65
52-Week Range	29.12 - 44.55
Beta	0.33
RSI	44.41
Earnings Date	Mar 16, 2026

About Center Laboratories

Center Laboratories, Inc., a pharmaceutical company, develops, manufactures, and sells pharmaceuticals in Taiwan and internationally. The company offers general medication pharmaceuticals comprising antipyretics and analgesics, bronchodilators, anti-inflammatory preparations, antihistamines, expectorants, narcotic antitussives and expectorants, gastrointestinal preparations, non-narcotic antitussives and expectorants, and other medicines. It also offers central nervous system medication consisting of treatments for cerebrovascular disease, deme...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1959
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4123

Financial Performance

In 2024, Center Laboratories's revenue was 1.62 billion, an increase of 16.06% compared to the previous year's 1.39 billion. Losses were -1.10 billion, 10.9% more than in 2023.